Clinical trials: Advanced Clear Cell Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)
The study consists of two parts, the first part is a randomized, open-label, active-controlled study to evaluate the efficacy and safety of fruquintinib in combination with sintilimab versus axitinib or everolimus monotherapy as…
- Trial name
- NCT05522231
- Testing
- fruquintinib+sintilimab, axitinib / everolimus, fruquintinib
- Where
- 48 sites in China
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Carcinoma, Renal Cell
Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics)
Information on the prevalence of advanced/metastatic renal cell carcinoma and its symptom burden is limited in commercially insured adult patients.
- Trial name
- NCT01381601
- Testing
- Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Renal Cell Carcinoma
A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread
The purpose of this study is in Part 1, to determine the safety of nivolumab, bempegaldesleukin (BEMPEG: NKTR-214), and Tyrosine Kinase Inhibitor (TKI) combination.
- Trial name
- PIVOT IO 011 (NCT04540705)
- Testing
- Nivolumab, Axitinib, Cabozantinib
- Where
- 39 sites in United States, Argentina and 6 more
- Volunteers
- 30 people
- Sponsor
- Bristol-Myers Squibb
Non-Small-Cell Lung Carcinoma, Renal Cell Carcinoma
ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer
The drug ABR-217620 is a combination of two proteins, one that recognizes tumor cells and one that triggers an attack on the tumor cells by activating some white blood cells belonging to the body's normal immune system.
- Conditions
- Non-Small-Cell Lung Carcinoma, Renal Cell Carcinoma, Pancreatic Cancer
- Trial name
- NCT00056537
- Testing
- ABR-217620
- Where
- 3 sites in United States, Norway and 1 more
- Volunteers
- 44 people
- Sponsor
- Active Biotech AB
Kidney Cancer
Arsenic Trioxide in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have…
- Trial name
- NCT00005069
- Testing
- arsenic trioxide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Kidney Cancer
Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma
The purpose of this study is to determine whether the combination of bevacizumab/temsirolimus is effective in patients with advanced renal carcinoma progressing after anti-VEGF treatment
- Trial name
- NCT01264341
- Testing
- Bevacizumab, Temsirolimus
- Where
- 8 sites in Greece
- Volunteers
- 39 people
- Sponsor
- Hellenic Cooperative Oncology Group
Carcinoma, Renal Cell
A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment
This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of atezolizumab given in combination with cabozantinib versus cabozantinib alone in participants with inoperable, locally…
- Trial name
- CONTACT-03 (NCT04338269)
- Testing
- Atezolizumab, Cabozantinib
- Where
- 135 sites in United States, Argentina and 13 more
- Volunteers
- 522 people
- Sponsor
- Hoffmann-La Roche
Urachal Cancer, Parathyroid Carcinoma
Agnostic Therapy in Rare Solid Tumors
The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors.
- Conditions
- Urachal Cancer, Parathyroid Carcinoma, Fibrolamellar Carcinoma, Angiosarcoma
- Trial name
- ANTARES (NCT06638931)
- Testing
- Nivolumab
- Where
- 5 sites in Brazil
- Volunteers
- 28 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer
In patients with recurrent or metastatic renal cell carcinoma, a preliminary evaluation of the safety and efficacy of sintilimab combined with axitinib in patients with advanced renal cell carcinoma was conducted.Progression-free…
- Trial name
- SAARCC (NCT04958473)
- Testing
- Sintilimab, Axitinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tianjin Medical University Second Hospital
Metastatic Disease, Renal Cell Carcinoma
Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC)
The ROSORC trial is a randomized study comparing the efficacy of a new association (sorafenib and IL-2) versus the standard therapy (sorafenib) in patients affected by different histotypes of metastatic RCC.
- Trial name
- ROSORC (NCT00609401)
- Testing
- Nexavar (Sorafenib), IL-2
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Italian Trial in Medical Oncology
Advanced Renal Cell Carcinoma
A Study to Collect Pre-existing Data on the Administration of Cabozantinib in Participants With Advanced Renal Cell Carcinoma (aRCC) Who Initiated Cabozantinib in 2nd Line in a Real-life Clinical Setting in France.
Cabozantinib is an orally bioavailable tyrosine kinase inhibitor (TKI) approved in patients with aRCC previously treated with a Vascular Endothelial Growth Factor (VEGF)-targeted therapy.
- Trial name
- OCTOPUS (NCT05444933)
- Where
- 28 sites in France
- Volunteers
- 252 people
- Sponsor
- Ipsen
Carcinoma, Renal Cell
Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma
This is a global, multi-centre, long-term, prospective, observational study to evaluate treatment patterns and clinical outcomes in patients with advanced or metastatic RCC treated for the first time with pazopanib.
- Trial name
- PRINCIPAL (NCT01649778)
- Testing
- Pazopanib
- Where
- 144 sites in United States, Argentina and 16 more
- Volunteers
- 662 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Kidney Carcinoma, Advanced Renal Cell Carcinoma
Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer
This phase I/II trial studies the side effects and best dose of mercaptopurine, and to see how well it works in treating patients with hereditary leiomyomatosis and renal cell carcinoma (HLRCC).
- Conditions
- Advanced Kidney Carcinoma, Advanced Renal Cell Carcinoma, Hereditary Leiomyomatosis and Renal Cell Carcinoma, Metastatic Kidney Carcinoma
- Trial name
- NCT07716735
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Carcinoma, Renal Cell, Melanoma
Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma
The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of GC1008, a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in previously treated patients with…
- Trial name
- NCT00356460
- Testing
- GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody, GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ ) Monoclonal Antibody
- Where
- 6 sites in United States
- Volunteers
- 29 people
- Sponsor
- Genzyme, a Sanofi Company
Solid Tumor, Adult, Solid Tumor Cancer
Study of DF6215 in Patients With Advanced Solid Tumors
A Phase I/Ib, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 Monotherapy and in Combination Therapy in Patients with Advanced…
- Trial name
- NCT06108479
- Testing
- DF6215, pembrolizumab, KEYTRUDA®
- Where
- 21 sites in United States, Australia and 1 more
- Volunteers
- 35 people
- Sponsor
- Dragonfly Therapeutics
Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
177LuPSMA in Renal Cell Carcinoma
This study aims to evaluate the efficacy and safety of 177Lu-PSMA-617 as a systemic therapy in patients with PSMA-positive advanced clear cell renal cell carcinoma (ccRCC).
- Conditions
- Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Kidney Cancer
- Trial name
- LASER (NCT06964958)
- Testing
- 177Lu-PSMA-617
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Dana-Farber Cancer Institute
Solid Tumors
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-303 as a monotherapy…
- Trial name
- NCT06158958
- Testing
- ABBV-303, Budigalimab
- Where
- 18 sites in United States, Israel and 1 more
- Volunteers
- 27 people
- Sponsor
- AbbVie
Adult Solid Neoplasm, Lung Carcinoid Tumor
Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and the best dose of trebananib and temsirolimus when given together in treating patients with solid tumors that are metastatic or cannot be removed by surgery.
- Conditions
- Adult Solid Neoplasm, Lung Carcinoid Tumor, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Renal Cell Carcinoma
- Trial name
- NCT01548482
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Temsirolimus
- Where
- 3 sites in Canada
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer, Advanced Renal Cell Carcinoma
PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer
This is a tissue and blood collection protocol requiring image-guided biopsies of metastatic prostate cancer and other genitourinary malignancies including renal cell carcinoma and urothelial carcinoma.
- Conditions
- Prostate Cancer, Advanced Renal Cell Carcinoma, Advanced Urothelial Carcinoma, Genitourinary Cancer
- Trial name
- NCT02735252
- Testing
- Systemic therapy, StrataNGS
- Where
- United States
- Volunteers
- 156 people
- Sponsor
- University of California, San Francisco
Renal Malignant Tumor
Predictive Imaging Features in Renal Cell Carcinoma
The investigators aimed to evaluate the role of some findings that can be detected in preoperative radiological imaging of kidney masses in predicting locally advanced disease.
- Trial name
- NCT05042089
- Testing
- No intervention will be applied.
- Where
- Turkey (Türkiye)
- Volunteers
- 92 people
- Sponsor
- Ankara Yildirim Beyazıt University